Film formulations containing dexmedetomidine and methods of producing them
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
1. A self-supporting, dissolvable, film, comprising:
(i) dexmedetomidine or a pharmaceutically acceptable salt thereof;
(ii) one or more first water-soluble hydroxypropyl cellulose polymers having a molecular weight of about 40,000 daltons;
(iii) one or more second water-soluble hydroxypropyl cellulose polymers having a molecular weight of about 140,000 daltons;
(iv) one or more third water-soluble hydroxypropyl cellulose polymers having a molecular weight of about 370,000 daltons; and
(v) one or more pharmaceutically acceptable carriers;
wherein the first water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 40,000 daltons is present at about 3% to about 8% w/w of the total film weight
wherein the second water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons is present at about 3% to about 8% w/w of the total film weight
wherein the third water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 370,000 daltons is present at about 20% to about 40% w/w of the total film weight
wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present at about 0.05% to about 3% weight/weight (w/w) of the total film weight, and
wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is substantially uniformly distributed throughout the film.
2. The film of claim 1 , wherein the pharmaceutically acceptable carriers are selected from the group consisting of: liquid carriers, flavors, sweeteners, refreshing agents, pH adjusting agents, permeation enhancers, plasticizers, bulking agents, surfactants, anti-foaming agents, and colorants.
3. The film of claim 1 , wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present in a dose of about 0.5 micrograms to about 200 micrograms.
4. The film of claim 1 , wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present in a dose of about 120 micrograms.
5. The film of claim 1 , further comprising a water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons, wherein said water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons is present at about 50% to about 60% w/w of the total film weight.
6. The film of claim 1 , wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present in a dose of about 30 micrograms.
7. The film of claim 1 , wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present in a dose of about 60 micrograms.
8. The film of claim 1 , wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is present in a dose of about 90 micrograms.